• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

    2/13/24 5:13:58 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    SC 13G/A 1 tv01811-repligencorp.htm SCHEDULE 13G/A repligencorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Repligen Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  759916109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  759916109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    31,387

    7.  SOLE DISPOSITIVE POWER

    5,004,124

    8.  SHARED DISPOSITIVE POWER

    74,137

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,078,261

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.10%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Repligen Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    41 Seyon Street, Building 1, Suite 100
    Waltham, MA 02453

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    759916109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $RGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    6/2/2026$145.00Outperform
    Wolfe Research
    5/15/2026$160.00Outperform
    RBC Capital Mkts
    4/17/2026$160.00Buy
    Rothschild & Co Redburn
    10/1/2025$150.00Buy
    HSBC Securities
    9/22/2025$155.00In-line → Outperform
    Evercore ISI
    7/22/2025$160.00Overweight
    Stephens
    6/24/2025$150.00Overweight
    Barclays
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Repligen with a new price target

    Wolfe Research resumed coverage of Repligen with a rating of Outperform and set a new price target of $145.00

    6/2/26 8:37:34 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts resumed coverage on Repligen with a new price target

    RBC Capital Mkts resumed coverage of Repligen with a rating of Outperform and set a new price target of $160.00

    5/15/26 8:30:16 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rothschild & Co Redburn initiated coverage on Repligen with a new price target

    Rothschild & Co Redburn initiated coverage of Repligen with a rating of Buy and set a new price target of $160.00

    4/17/26 8:13:33 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    SEC Filings

    View All

    Repligen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - REPLIGEN CORP (0000730272) (Filer)

    5/15/26 8:09:23 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Repligen Corporation

    10-Q - REPLIGEN CORP (0000730272) (Filer)

    5/6/26 4:08:42 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REPLIGEN CORP (0000730272) (Filer)

    5/5/26 7:06:38 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

    WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that de

    5/22/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

    WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed "Driving Sustainable Growth Together", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three

    5/20/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

    WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a globa

    5/7/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    8/12/25 12:47:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    3/18/25 3:58:05 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    6/14/24 6:07:59 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pax Margaret was granted 995 shares, increasing direct ownership by 49% to 3,011 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:06 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Eglinton Manner Carrie was granted 995 shares, increasing direct ownership by 22% to 5,461 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mhatre Rohin was granted 995 shares, increasing direct ownership by 25% to 5,014 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/18/26 4:05:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    View All

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    Repligen Appoints Jacob Johnson As Vice President Investor Relations

    WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

    4/8/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

    BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

    12/16/24 8:11:00 AM ET
    $BLFS
    $RGEN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $RGEN
    Financials

    Live finance-specific insights

    View All

    Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

    First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026. Olivier Loeillot, President and Chief Executive Officer

    5/5/26 7:00:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen to Report First Quarter 2026 Financial Results

    WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w

    4/22/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

    Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve-

    2/24/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    11/14/24 1:22:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    9/10/24 5:08:30 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    2/14/24 10:02:59 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care